Companies

BMS may have ditched an antibody-drug conjugate partnership with Eisai, but the Phase II pipeline for ADCs remains strong across the industry.

Three new vaccines to prevent RSV infections in seniors and sales trends in pediatric vaccines highlight a shift away from childhood vaccines and a possible age-related immunity deficit.

The delayed decision from the CHMP is another rejection for Syfovre but Apellis still hopes the regulator may be convinced in a second review later this year.

Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.

The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.

An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.

Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.

The companies are set to present Phase III results from their rival myostatin inhibitor drugs for spinal muscular atrophy in Q4, while also fast-tracking the candidates in obesity studies.

Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.

The success in the NIAGRA bladder cancer study is welcome, but another failure in NSCLC means AstraZeneca has more riding on the AEGEAN study, with an FDA advisory board to review the lung cancer data due shortly.

A new muscle-building front is opening in the fight against obesity, with Lilly among the leaders. But it plans to remain tight-lipped on upcoming Phase II data for its myostatin inhibitor in combination with Novo’s Wegovy for fear of playing into the hands of its rival.

The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.

After the Phase III failure of xevinapant, the German group will need to cut deals and do better in a rare cancer if it is to turn its fortunes around.

J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.

Lilly’s incretin looks set to add obstructive sleep apnea to its label – an indication in which Novo Nordisk has so far shown no interest.

Presenting at conferences allows companies to showcase data on new drugs and secure licensing partners, as well as further investment by shareholders. But two presentations at the recent EHA conference had the opposite effect.